Invesfera Newsroom
RAS-Targeted Breakthrough: Reshaping Pancreatic Cancer Investment
The EMA's recommendation for Rasonque, an oral RAS-targeted drug, signals a pivotal moment for oncology, opening significant new investment opportunities in a high-need therapeutic area.
